DUBLIN , Aug. 19, 2022 /PRNewswire/ -- The "Global Prosthetic Heart Valve Market Size, Share & Industry Trends Analysis Report By End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers), By Product (Transcatheter, Tissue, and Mechanical), By Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The Global Prosthetic Heart Valve Market size is expected to reach $13.3 billion by 2028, rising at a market growth of 10.7% CAGR during the forecast period. Materials like titanium and carbon are used to make mechanical heart valves. They are typically made up of two leaflets and a metal ring encircled by a knitted fabric ring that is sewed onto the heart in place of the native valve. Aortic and mitral replacement operations are available in a variety of models. Mechanical valves have the advantage of being extremely durable. These valves, on the other hand, provide a substrate on which blood clots can easily form. An opening through which blood flows and a device that closes and opens the orifice make up artificial heart valves. Mechanical devices made of synthetic materials and biological or tissue valves made of animal or human tissue are the two forms of artificial heart valves. Biological valves are typically employed in people over the age of 65 who are unable to take anticoagulants.
Mechanical valves are advised for individuals under the age of 40 who have a mechanical valve at another position, have had a stroke, or require double valve replacement. These valves necessitate the use of anti-coagulants by the patient. Mechanical valves can be classified into three categories based on how they open and close. A revolving ball, a tilting disk, or two semispherical hinged leaflets are examples of these systems. The first is based on a ball-in-cage design, which employs a rubber ball that oscillates within a cobalt-chromium alloy metal cage. When the valve opens, blood flows between the ball and the housing through a primary and secondary orifice. A circular disk is held in place by wire-like arms that protrude into the orifice in the tilting disk valve. The primary orifice is divided into two unequal orifices when the disk opens. A hinge mechanism connects two semicircular leaflets to the orifice enclosure in the current configuration. During the opening process, the leaflets separate, resulting in three flow zones in the center as well as on the sides. COVID-19 Impact Analysis
During the pandemic, surgeries were delayed and production of prosthetic heart valves was also decreased or suspended due to government restrictions and limitations, causing the prosthetic heart valve market to experience a drop in the growth during the first wave of COVID-19.
Coronaviruses are a wide family of SARS (severe acute respiratory syndrome) viruses that cause illnesses ranging from ordinary cold to serious respiratory illnesses. The execution of lockdown postponed the surgical operation for implanting a prosthetic heart valve as well as the manufacturing of prosthetic heart valves, resulting in gradual market disruption. Market Growth Factors:
Rising prevalence of cardiovascular diseases
With the rapidly evolving lifestyles of people across the world, the occurrence of various diseases and disorders is also rising as a result. One of the major disorders that can be caused by the changing living patterns of people is cardiovascular disease. Unhealthy food, physical inactivity, cigarette consumption, and problematic alcohol consumption are the major behavioral risk factors for heart disease and stroke.
People may experience symptoms, such as high blood pressure, high blood glucose, high blood lipids, or overweight or obesity as a result of behavioral risk factors. These intermediate risk factors are detectable in primary care settings and imply a higher risk of stroke, heart attack, heart failure, and other consequences. The rapid surge in the geriatric population
The geriatric population all over the world is significantly increasing. According to the United Nations Organization, in 2019, the world's population of people aged 65 and up totaled 703 million. In 2050, the number of geriatric people is anticipated to reach 1.5 billion. The proportion of people aged 65 and up in the global population climbed from 6% in 1990 to 9% in 2019. By 2050, that percentage is expected to climb to 16%, implying that one in every six individuals worldwide is expected to be 65 or older. In the years 2015-2020, a 65-year-old person should expect to live an additional 17 years on average over the world. Marketing Restraining Factor:
Mechanical heart valve failure occurs in various cases after the completion of an artificial heart valve transplant. Though structural damage is uncommon, infections and blood clots may necessitate the replacement of some of them. Clots can either open or seal the mechanical valve, causing stenosis, insufficiency, or a combination of the two.
Some clots can break free from the prosthetic valve and move to the arteries and blood vessels that supply the heart (coronary arteries) or the brain (carotid arteries), resulting in a stroke or heart attack. Mechanical heart valves have a higher risk of thrombotic or thromboembolic consequences.
Key Topics Covered: Chapter 1. Market Scope & Methodology Chapter 2. Market Overview 2.1 Introduction 2.1.1 Overview 2.1.1.1 Market composition and scenario 2.2 Key Factors Impacting the Market 2.2.1 Market Drivers 2.2.2 Market Restraints Chapter 3. Competition Analysis - Global 3.1 Cardinal Matrix 3.2 Recent Industry Wide Strategic Developments 3.2.1 Approvals and Trials 3.2.2 Product Launches and Product Expansions 3.2.3 Acquisition and Mergers 3.3 Top Winning Strategies 3.3.1 Key Leading Strategies Percentage Distribution (2018-2022) 3.3.2 Key Strategic Move (Acquisitions and Mergers 2019, Mar - 2021, Oct) Leading Players Chapter 4. Global Prosthetic Heart Valve Market by End User 4.1 Global Hospitals & Cardiac Centers Market by Region 4.2 Global Ambulatory Surgical Centers & Others Market by Region Chapter 5. Global Prosthetic Heart Valve Market by Product 5.1 Global Transcatheter Market by Region 5.2 Global Tissue Market by Region 5.3 Global Mechanical Market by Region Chapter 6. Global Prosthetic Heart Valve Market by Region Chapter 7. Company Profiles 7.1 Boston Scientific Corporation 7.1.1 Company Overview 7.1.2 Financial Analysis 7.1.3 Segmental and Regional Analysis 7.1.4 Research & Development Expense 7.1.5 Recent strategies and developments 7.1.5.1 Product Launches and Product Expansions 7.1.5.2 Acquisition and Mergers 7.1.6 SWOT Analysis 7.2 Medtronic PLC 7.2.1 Company overview 7.2.2 Financial Analysis 7.2.3 Segmental and Regional Analysis 7.2.4 Research & Development Expenses 7.2.5 Recent strategies and developments 7.2.5.1 Approvals and Trials 7.2.6 SWOT Analysis 7.3 Abbott Laboratories 7.3.1 Company Overview 7.3.2 Financial Analysis 7.3.3 Segmental and Regional Analysis 7.3.4 Research & Development Expense 7.3.5 Recent strategies and developments 7.3.5.1 Product Launches and Product Expansions 7.3.5.2 Acquisition and Mergers 7.3.5.3 Approvals and Trials 7.3.6 SWOT Analysis 7.4 Meril Life Sciences Private Limited 7.4.1 Company Overview 7.4.2 Recent strategies and developments 7.4.2.1 Product Launches and Product Expansions 7.5 Colibri Heart Valve LLC 7.5.1 Company Overview 7.6 Artivion, Inc. (CryoLife, Inc.) 7.6.1 Company Overview 7.6.2 Financial Analysis 7.6.3 Segmental and Regional Analysis 7.6.4 Research & Development Expenses 7.6.5 Recent strategies and developments 7.6.5.1 Acquisition and Mergers 7.7 TTK Healthcare Limited 7.7.1 Company Overview 7.7.2 Financial Analysis 7.7.3 Segmental and Regional Analysis 7.7.4 Research & Development Expenses 7.8 Edwards Lifesciences Corporation 7.8.1 Company Overview 7.8.2 Financial Analysis 7.8.3 Regional Analysis 7.8.4 Research & Development Expenses 7.8.5 Recent strategies and developments 7.8.5.1 Acquisition and Mergers 7.8.5.2 Approvals and Trials 7.9 JenaValve Technology, Inc. 7.9.1 Company Overview 7.9.2 Recent strategies and developments 7.9.2.1 Geographical Expansions 7.10. Micro Interventional Devices, Inc. 7.10.1 Company Overview 7.10.2 Recent strategies and developments 7.10.2.1 Approvals and Trials
For more information about this report visit https://www.researchandmarkets.com/r/iho90c
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
LOGO: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/the-worldwide-prosthetic-heart-valve-industry-is-expected-to-reach-13-3-billion-by-2028--301609144.html
Markets correspondent Jared Blikre takes a look at the declining pricing for cryptocurrencies bitcoin and ethereum as the FDIC issue letters to five crypto companies.
In the world of stock legends, George Soros stands out. While his political activities have been a lightning rod for controversy, no one can doubt his financial acumen. After all, he’s the ‘man who broke the Bank of England,’ and made a billion dollars in one day when he shorted the Pound Sterling back in 1992. His hedge fund, Soros Fund Management, showed three decades of sustained gains, averaging 30% annual returns through the year 2000. During this time, and today in the management of his pe
Yahoo Finance Live co-anchor Seana Smith looks at several trending stocks moving in after-hours trading.
The stock rose as much as 272% but is up about 175% as of 1:25 p.m. ET. The tech stock's gain came on the day of its initial public offering (IPO). Given the way the stock is soaring, the market apparently thinks the IPO was underpriced.
The Food and Drug Administration authorized Novavax Inc.'s COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. and BioNTech SE , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults
The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.
A 20-year-old USC student has made a $110 million profit from trading meme stock favorite Bed Bath & Beyond, following a frenzy in Wednesday’s trading session.
Prices at the pump have fallen again, but the summer decline is mostly over, according to industry watchers.
Shares of StoneCo (NASDAQ: STNE), a cloud-based technology platform, plummeted Friday morning after the company reported its second-quarter results, which disappointed investors, and announced yet another shift to its management team. The company reported non-GAAP (adjusted) earnings of 0.25 Brazilian reals (equivalent to $0.05), which was an increase from a loss of 0.48 reals in the year-ago quarter, but was below Wall Street's consensus estimate of about 0.57 reals, or $0.11 per share. StoneCo's revenue in the quarter was 2.3 billion reals (about $442 million), 5% higher than the company's guidance, and up 275% from the year-ago quarter.
Back up the EV on shares of General Motors, says this one analyst.
The $18 billion market for colon-cancer screening perfectly illustrates the difference between innovation and hype. It has implications for Exact Sciences , Guardant Health and others setting their sights on the market. A number of Wall Street analysts say that liquid biopsies can claim a significant share of the colon-cancer-screening market.
The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.
It's no wonder Altria's (NYSE: MO) stock has lost more than a fifth of its value in just a couple of months. Marketing partner Philip Morris International (NYSE: PM) is getting cold feet on working with Altria to sell its IQOS heated tobacco device while also just acquiring the leading competitor to Altria's own smokeless tobacco products. At the same time, the federal government all but obliterated Altria's $13 billion investment in Juul Labs, the one-time electronic-cigarette leader.
For investors looking to maximize their wealth by the time they retire, the following pair of beaten-down businesses that possess strong growth capabilities are a worthwhile place to start. Freelance marketplace operator Fiverr (NYSE: FVRR) was a pandemic-lockdown superstar. Although Fiverr's stock price is down 65% in 2022 and off 82% from its all-time high, the freelance shop is still growing, albeit at a slower rate as SMBs became more cautious due to rampant inflation and rising energy costs and interest rates.
(Bloomberg) -- Warren Buffett’s Berkshire Hathaway Inc. won approval from US regulators to buy as much as 50% of Occidental Petroleum Corp. after spending months snapping up its shares. Occidental’s stock had its biggest gain in five months.Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapM
(Bloomberg) -- Billionaire Ryan Cohen pocketed a $68.1 million profit from the sale of his stake in Bed Bath & Beyond Inc., scoring a 56% gain on an investment he held for roughly seven months.Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapMueller Memo Advising Barr on Trump Findings Is O
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Melius Research Director of Airlines & Travel Research Conor Cunningham joins Yahoo Finance Live to discuss summer travel disruptions, airline operations and profitability, and the outlook for air travel.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus
The Federal Energy Regulatory Commission filing could mean that Berkshire Hathaway will continue to increase its stake in Occidental.